Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00134511 |
The Torcetrapib project was terminated on December 2, 2006 due to safety findings.
To evaluate the efficacy and safety of the lipid drug Torcetrapib/atorvastatin in patients with genetically known disorder of extremely high cholesterol
Condition | Intervention | Phase |
---|---|---|
Hypercholesterolemia, Familial |
Drug: Torcetrapib/atorvastatin |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase 3 Multi-Center, Open Label, Forced Titration Study To Evaluate The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Combination Administered Orally, Once Daily (Qd) In Patients With Homozygous Familial Hypercholesterolaemia |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Massachusetts | |
Pfizer Investigational Site | |
Boston, Massachusetts, United States, 02114 | |
Canada, Quebec | |
Pfizer Investigational Site | |
Chicoutimi, Quebec, Canada, G7H 5H6 | |
Pfizer Investigational Site | |
Ste-Foy, Quebec, Canada, G1V 4M6 | |
South Africa | |
Pfizer Investigational Site | |
Bloemfontein, South Africa, 9301 | |
Pfizer Investigational Site | |
Cape Town, South Africa, 7925 | |
South Africa, Johannesburg | |
Pfizer Investigational Site | |
Parktown, Johannesburg, South Africa, 2193 |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Study ID Numbers: | A5091027 |
Study First Received: | August 22, 2005 |
Last Updated: | November 5, 2007 |
ClinicalTrials.gov Identifier: | NCT00134511 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Antimetabolites Lipid Metabolism, Inborn Errors Hyperlipidemias Metabolic Diseases Antilipemic Agents Hyperlipoproteinemia Type II Anticholesteremic Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Metabolism, Inborn Errors |
Genetic Diseases, Inborn Torcetrapib Hypercholesterolemia, Autosomal Dominant Hypercholesterolemia Metabolic Disorder Hyperlipoproteinemias Dyslipidemias Atorvastatin Lipid Metabolism Disorders |
Antimetabolites Lipid Metabolism, Inborn Errors Hyperlipidemias Metabolic Diseases Molecular Mechanisms of Pharmacological Action Antilipemic Agents Hyperlipoproteinemia Type II Enzyme Inhibitors Anticholesteremic Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors |
Pharmacologic Actions Metabolism, Inborn Errors Genetic Diseases, Inborn Torcetrapib Therapeutic Uses Hypercholesterolemia Dyslipidemias Hyperlipoproteinemias Atorvastatin Lipid Metabolism Disorders |